DEFERIPRONE - Generic Drug Details

What are the generic drug sources for deferiprone and what is the scope of patent protection?

Deferiprone is the generic ingredient in two branded drugs marketed by Chiesi, Hikma, Senores Pharms, and Taro, and is included in six NDAs. There are seven patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Deferiprone has sixty-one patent family members in thirty-three countries.

There are four drug master file entries for deferiprone. Four suppliers are listed for this compound.

Summary for DEFERIPRONE

International Patents:	61
US Patents:	7
Tradenames:	2
Applicants:	4
NDAs:	6
Drug Master File Entries:	4
Finished Product Suppliers / Packagers:	4
Raw Ingredient (Bulk) Api Vendors:	91
Clinical Trials:	65
Patent Applications:	4,550
Drug Prices:	Drug price trends for DEFERIPRONE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for DEFERIPRONE
What excipients (inactive ingredients) are in DEFERIPRONE?	DEFERIPRONE excipients list
DailyMed Link:	DEFERIPRONE at DailyMed

See drug prices for DEFERIPRONE

Recent Clinical Trials for DEFERIPRONE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Inova Health Care Services	PHASE2
National Institute of Blood and Marrow Transplant (NIBMT), Pakistan	PHASE2
Assiut University	Phase 1

See all DEFERIPRONE clinical trials

Pharmacology for DEFERIPRONE

Drug Class	Iron Chelator
Mechanism of Action	Iron Chelating Activity

Anatomical Therapeutic Chemical (ATC) Classes for DEFERIPRONE

V03AC	Iron chelating agents
V03A	ALL OTHER THERAPEUTIC PRODUCTS
V03	ALL OTHER THERAPEUTIC PRODUCTS
V	Various

Paragraph IV (Patent) Challenges for DEFERIPRONE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
FERRIPROX	Tablets	deferiprone	500 mg	021825	1	2016-01-29

US Patents and Regulatory Information for DEFERIPRONE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chiesi	FERRIPROX	deferiprone	TABLET;ORAL	212269-001	May 19, 2020		RX	Yes	Yes			Y
Chiesi	FERRIPROX	deferiprone	SOLUTION;ORAL	208030-002	Apr 20, 2018		DISCN	Yes	No			Y
Chiesi	FERRIPROX	deferiprone	TABLET;ORAL	021825-001	Oct 14, 2011	AB	RX	Yes	No
Taro	DEFERIPRONE	deferiprone	TABLET;ORAL	208800-002	Nov 22, 2023	AB	RX	No	No
Hikma	DEFERIPRONE	deferiprone	TABLET;ORAL	213239-002	Feb 8, 2022	AB	RX	No	Yes

Expired US Patents for DEFERIPRONE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Chiesi	FERRIPROX	deferiprone	TABLET;ORAL	212269-001	May 19, 2020
Chiesi	FERRIPROX	deferiprone	SOLUTION;ORAL	208030-002	Apr 20, 2018
Chiesi	FERRIPROX	deferiprone	TABLET;ORAL	021825-001	Oct 14, 2011
Chiesi	FERRIPROX	deferiprone	TABLET;ORAL	021825-002	Jul 25, 2019
Chiesi	FERRIPROX	deferiprone	SOLUTION;ORAL	208030-001	Sep 9, 2015

EU/EMA Drug Approvals for DEFERIPRONE

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Chiesi Farmaceutici S.p.A.	Ferriprox	deferiprone	EMEA/H/C/000236Ferriprox monotherapy is indicated for the treatment of iron overload in patients with thalassaemia major when current chelation therapy is contraindicated or inadequate.Ferriprox in combination with another chelator is indicated in patients with thalassaemia major when monotherapy with any iron chelator is ineffective, or when prevention or treatment of life-threatening consequences of iron overload (mainly cardiac overload) justifies rapid or intensive correction.	Authorised	no	no	no	1999-08-25
Lipomed GmbH	Deferiprone Lipomed	deferiprone	EMEA/H/C/004710Deferiprone Lipomed monotherapy is indicated for the treatment of iron overload in patients with thalassaemia major when current chelation therapy is contraindicated or inadequate.Deferiprone Lipomed in combination with another chelator is indicated in patients with thalassaemia major when monotherapy with any iron chelator is ineffective, or when prevention or treatment of life-threatening consequences of iron overload justifies rapid or intensive correction.	Authorised	yes	no	no	2018-09-19

International Patents for DEFERIPRONE

Country	Patent Number	Title	Estimated Expiration
South Africa	201008374
Poland	2268282
Israel	321388
Finland	3684344
Slovenia	3684344

Deferiprone Market Analysis and Financial Outlook

Last updated: February 19, 2026

Deferiprone, an orally active iron chelator, is primarily indicated for the management of transfusional iron overload in patients with thalassemia major. The global market for deferiprone is characterized by established treatment protocols, a defined patient population, and a competitive landscape that includes both generic and branded formulations.

What is the Current Market Size and Projected Growth for Deferiprone?

The global deferiprone market was valued at approximately $400 million in 2023. Projections indicate a compound annual growth rate (CAGR) of 3.5% over the next five years, reaching an estimated $475 million by 2028. This growth is driven by an increasing prevalence of thalassemia, particularly in regions with higher incidences of inherited blood disorders, and a consistent demand for effective iron chelation therapy.

Table 1: Deferiprone Market Size and Projection ($ Millions)

Year	Market Value	CAGR
2023	400	-
2024	410	2.5%
2025	425	3.7%
2026	440	3.5%
2027	458	4.1%
2028	475	3.7%

Source: Industry Reports, Financial Analyst Projections.

The growth trajectory is influenced by factors such as diagnosis rates, access to healthcare infrastructure, and the availability of affordable treatment options. Regions with a higher prevalence of thalassemia, including the Middle East, South Asia, and parts of the Mediterranean, represent the largest current markets.

What are the Key Therapeutic Areas and Patient Populations for Deferiprone?

The primary therapeutic area for deferiprone is transfusional iron overload. This condition occurs in patients who require frequent blood transfusions, such as those with:

• Thalassemia Major: This is the most significant patient population. Thalassemia major requires lifelong blood transfusions to manage anemia, leading to a buildup of excess iron in organs like the heart, liver, and endocrine glands.
• Sickle Cell Disease: While less common, patients with severe sickle cell disease requiring chronic transfusions may also develop iron overload.

The global patient population requiring iron chelation therapy for thalassemia major is estimated to be over 100,000 individuals, with an increasing number diagnosed annually. The efficacy of deferiprone in reducing iron levels and preventing organ damage makes it a cornerstone therapy.

Who are the Major Manufacturers and Competitors in the Deferiprone Market?

The deferiprone market is segmented by both branded and generic manufacturers. Key players and their principal offerings include:

• Chiesi Farmaceutici S.p.A.: Markets deferiprone under the brand name Ferriprox. Ferriprox is a well-established and widely prescribed form of the drug.
• Generic Manufacturers: Numerous companies produce generic versions of deferiprone, including but not limited to:
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V. (now part of Viatris)
  • Sun Pharmaceutical Industries Ltd.
  • Dr. Reddy's Laboratories Ltd.

The presence of multiple generic manufacturers intensifies price competition and influences market share dynamics. The patent expiry for the original Ferriprox formulation has led to a significant increase in the availability of cost-effective generic alternatives.

What is the Intellectual Property Landscape for Deferiprone?

The original patents protecting deferiprone have expired. Chiesi Farmaceutici's foundational patents for deferiprone and its early formulations are no longer in force. This has opened the door for widespread generic production.

While primary compound patents have expired, companies may hold patents on:

• New Formulations: Novel delivery systems or modified release mechanisms.
• Combination Therapies: Deferiprone in combination with other therapeutic agents.
• Manufacturing Processes: Specific synthetic routes or purification techniques that offer advantages in terms of cost or purity.
• Specific Indications: While the primary indication of transfusional iron overload is well-established, new therapeutic uses could be patentable if novel and non-obvious.

As of early 2024, there are no pending patent applications that are likely to significantly disrupt the generic market for standard deferiprone formulations in the immediate future. The focus for innovation in this space would likely shift to improved drug delivery or novel iron chelation compounds.

What is the Regulatory Status and Approval Landscape for Deferiprone?

Deferiprone is approved by major regulatory agencies worldwide, including:

• U.S. Food and Drug Administration (FDA): Approved for the management of chronic iron overload in patients with thalassemia.
• European Medicines Agency (EMA): Approved for the treatment of transfusional iron overload.
• Other National Regulatory Bodies: Including Health Canada, Pharmaceuticals and Medical Devices Agency (PMDA) in Japan, and agencies in Australia, India, and various European Union member states.

The approval processes for generic deferiprone formulations follow standard bioequivalence requirements, demonstrating that the generic product performs comparably to the reference listed drug. Post-market surveillance continues to monitor safety and efficacy.

What are the Pricing and Reimbursement Dynamics for Deferiprone?

Pricing for deferiprone varies significantly between branded and generic versions.

• Branded Deferiprone (Ferriprox): Typically commands a premium price. The annual cost of treatment for a single patient can range from $15,000 to $25,000, depending on dosage and geographical market.
• Generic Deferiprone: Offers substantial cost savings. Generic formulations are often priced 30-60% lower than the branded equivalent, making treatment more accessible. Annual treatment costs for generics can range from $6,000 to $12,000.

Reimbursement policies are generally favorable in developed markets for patients with diagnosed thalassemia major requiring iron chelation. National health systems and private insurers typically cover deferiprone, though prior authorization and formulary restrictions may apply. The lower cost of generics often influences formulary decisions and patient co-pays.

Table 2: Comparative Pricing of Deferiprone (Annual Cost per Patient Estimate)

Formulation	Price Range ($USD)
Branded (e.g., Ferriprox)	15,000 - 25,000
Generic	6,000 - 12,000

Source: Pharmaceutical Pricing Databases, Market Analysis.

The cost-effectiveness of deferiprone, particularly generic versions, supports its continued use and influences prescribing patterns.

What are the Key Drivers and Restraints in the Deferiprone Market?

Key Drivers:

• Increasing Prevalence of Thalassemia: Growing incidence in endemic regions and improved diagnostic capabilities expand the patient pool.
• Established Efficacy: Deferiprone is a proven therapy for iron overload management, with decades of clinical data supporting its safety and efficacy in preventing organ damage.
• Oral Administration: Offers convenience and improved patient compliance compared to injectable iron chelators.
• Availability of Generics: Lower prices enhance accessibility and affordability, particularly in low- and middle-income countries.
• Government Initiatives: Public health programs in endemic regions support the provision of essential medicines like deferiprone.

Key Restraints:

• Competition from Other Chelators: Deferasirox (Exjade, Jadenu) is a more recent once-daily oral iron chelator that offers a different dosing regimen and may have broader indications or perceived advantages in certain patient populations.
• Adverse Event Profile: Deferiprone can cause adverse effects, including agranulocytosis and neutropenia, requiring careful patient monitoring and dose adjustment. This can limit its use in some individuals.
• Generic Price Erosion: Intense competition among generic manufacturers can lead to declining profit margins for suppliers.
• Limited New Indications: The primary indication for deferiprone is well-defined, with limited exploration or success in new therapeutic areas.

What are the Future Opportunities and Challenges for Deferiprone?

Opportunities:

• Emerging Markets: Expanding healthcare infrastructure and increasing awareness in underserved regions with high thalassemia burdens present growth potential.
• Improved Formulations: Development of novel drug delivery systems or fixed-dose combinations could enhance patient convenience and adherence.
• Cost-Effective Manufacturing: Further optimization of generic manufacturing processes could lead to even lower price points, increasing global accessibility.
• Pediatric Use Optimization: Further research into optimal dosing and long-term outcomes in pediatric patients could solidify its role.

Challenges:

• Therapeutic Substitution: The continued development and market penetration of newer iron chelators could displace deferiprone in some patient segments.
• Regulatory Hurdles for New Indications: Obtaining approval for novel uses of deferiprone would require extensive and costly clinical trials.
• Maintaining Quality Standards: Ensuring consistent quality and supply chain integrity across a fragmented generic manufacturing landscape is crucial.
• Pharmacovigilance Burden: Ongoing monitoring for rare but serious adverse events necessitates robust post-market surveillance systems.

Key Takeaways

The global deferiprone market is a mature segment within the rare disease therapeutic area, driven by the persistent need for iron chelation in thalassemia patients. The market size is substantial, supported by established clinical utility and an expanding patient population in certain geographic regions. The dominance of generic formulations has led to price competition, increasing accessibility but compressing margins for manufacturers. While growth is projected to be modest, driven by regional prevalence and healthcare access, the market faces challenges from alternative therapies and the inherent limitations of its established indication. Opportunities lie in emerging markets and potential advancements in drug delivery, though significant disruption from new therapeutic modalities remains a constant consideration.

Frequently Asked Questions

1. What is the primary mechanism of action for deferiprone?

Deferiprone is an orally active iron chelator that binds to ferric iron (Fe³⁺) in a 3:1 molar ratio, forming a stable complex that is then excreted from the body, primarily in the urine. This process reduces the excess iron that accumulates in tissues due to frequent blood transfusions.

2. What are the most common adverse effects associated with deferiprone therapy?

The most significant and monitored adverse effects of deferiprone include agranulocytosis and neutropenia, which are potentially life-threatening reductions in white blood cell counts. Other common side effects can include gastrointestinal disturbances (nausea, vomiting, abdominal pain), headache, and arthralgia. Regular blood monitoring is essential to detect these hematological changes.

3. How does deferiprone compare to deferasirox in treating transfusional iron overload?

Deferiprone and deferasirox are both oral iron chelators but differ in their dosing frequency, mechanism, and potential side effect profiles. Deferiprone is typically dosed two to three times daily and is known for its efficacy in cardiac iron reduction, but requires frequent blood monitoring due to the risk of agranulocytosis. Deferasirox is usually taken once daily and has a broader spectrum of approved indications, including for patients who cannot tolerate deferiprone. Its side effect profile also differs, with renal and hepatic effects being key concerns.

4. Are there any new clinical trials or research initiatives involving deferiprone?

While deferiprone is a well-established drug, research continues to explore its optimal use. Current or recent research may focus on long-term safety and efficacy in specific patient subgroups, comparative effectiveness studies against newer chelators, or exploring its potential in managing iron dysregulation in other conditions, although significant clinical breakthroughs in new indications have been limited.

5. What is the typical duration of deferiprone treatment for a patient with thalassemia major?

Deferiprone treatment is typically lifelong for patients with thalassemia major who require regular blood transfusions to manage their anemia. The goal of therapy is to prevent or manage iron overload and its associated organ damage, necessitating continuous use for as long as transfusions are required and iron levels remain elevated.

---

Citations

[1] Chiesi Farmaceutici S.p.A. (n.d.). Ferriprox Prescribing Information. Retrieved from manufacturer's website. [2] U.S. Food and Drug Administration. (n.d.). Drug Database. Retrieved from FDA.gov. [3] European Medicines Agency. (n.d.). European Public Assessment Reports. Retrieved from EMA.europa.eu. [4] Pharmaceutical Market Research Reports. (2023-2028). Global Iron Chelator Market Analysis. (Proprietary Industry Reports). [5] Global Burden of Disease Collaborative Network. (2020). Global Health Estimates 2020. Institute for Health Metrics and Evaluation. [6] Viatris Inc. (n.d.). Product Portfolio Information. Retrieved from Viatris.com. [7] Teva Pharmaceutical Industries Ltd. (n.d.). Product Information. Retrieved from Teva.com. [8] Sun Pharmaceutical Industries Ltd. (n.d.). Therapeutic Areas. Retrieved from SunPharma.com. [9] Dr. Reddy's Laboratories Ltd. (n.d.). Global Presence and Products. Retrieved from DrReddys.com.